Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Country/Region as subject
Language
Affiliation country
Publication year range
1.
Antimicrob Agents Chemother ; 41(5): 1178-81, 1997 May.
Article in English | MEDLINE | ID: mdl-9145896

ABSTRACT

We studied the efficacies of ofloxacin, rifampin, and clindamycin in a Staphylococcus aureus abscess model and seven antimicrobial regimens in an intracellular killing assay. Ofloxacin plus rifampin was the most effective regimen in the abscess model, and rifampin and ofloxacin were the most active regimens in the intracellular killing assay.


Subject(s)
Abscess/drug therapy , Anti-Infective Agents/therapeutic use , Antibiotics, Antitubercular/therapeutic use , Clindamycin/therapeutic use , Ofloxacin/therapeutic use , Rifampin/therapeutic use , Staphylococcal Infections/drug therapy , Animals , Anti-Infective Agents/blood , Antibiotics, Antitubercular/blood , Clindamycin/blood , Microbial Sensitivity Tests , Models, Biological , Ofloxacin/blood , Rabbits , Rats , Rifampin/blood , Staphylococcus aureus/drug effects
2.
Arch Intern Med ; 152(3): 554-7, 1992 Mar.
Article in English | MEDLINE | ID: mdl-1546918

ABSTRACT

STUDY OBJECTIVE: The purpose of this study was to assess and compare the impact of voluntary compliance and enforced compliance with institutional guidelines for initiating third-generation cephalosporin therapy. DESIGN: An audit of third-generation cephalosporin use during a 6-month period shortly after ceftriaxone and ceftazidime were added to the hospital formulary already containing cefotaxime was performed. During this period, compliance to institutional guidelines for initiating therapy was voluntary. A follow-up audit during a similar 6-month period was performed to assess compliance with institutional guidelines shortly after an enforcement policy was placed in effect. The results of these two audits were compared to assess usage patterns of these cephalosporins, compliance rates with institutional guidelines for initiating therapy, use of susceptibility testing to guide therapy, effect of use of these drugs on susceptibility patterns within the hospital, and third-generation cephalosporin costs during periods when institutional policy was unenforced and enforced. RESULTS: Only 24.2% of 66 courses of third-generation cephalosporins were initiated in compliance with institutional guidelines during the initial audit period. Susceptibility testing revealed an organism susceptible to a first-generation cephalosporin in 13 courses but in only six instances was a switch to the more narrow-spectrum antibiotic performed. At the time routine susceptibility testing to ceftazidime and ceftriaxone was instituted, 92% of Enterobacter cloacae were sensitive to ceftriaxone and 89% of Pseudomonas aeruginosa were sensitive to ceftazidime. Fifteen months later, when voluntary compliance to institutional policy was terminated, 70% of E cloacae were sensitive to ceftriaxone and 73% of P aeruginosa were sensitive to ceftazidime. During the last 6 months of this period, pharmacy expenditures totaled $50,000. The second audit revealed 85.4% of 48 courses of treatment complied with guidelines for initiating therapy. Since enforcement was instituted, sensitivity of E cloacae to ceftriaxone has risen to 88% and sensitivity of P aeruginosa to ceftazidime has increased to 80%. Pharmacy expenditures decreased to $23,000.


Subject(s)
Bacterial Infections/drug therapy , Cephalosporins/therapeutic use , Drug Utilization/standards , Hospitals, Teaching/standards , Medical Audit , Bacterial Infections/mortality , Cephalosporins/economics , Drug Resistance, Microbial , Enterobacter cloacae/drug effects , Hospital Bed Capacity, 300 to 499 , Humans , Microbial Sensitivity Tests , Missouri , Prospective Studies , Pseudomonas aeruginosa/drug effects , Staphylococcus aureus/drug effects , Survival Rate
3.
Antimicrob Agents Chemother ; 35(11): 2335-9, 1991 Nov.
Article in English | MEDLINE | ID: mdl-1804006

ABSTRACT

A rabbit perforated-capsule model was utilized to study antimicrobial efficacy in treating 2-week-old Staphylococcus aureus abscesses. Animals received either ciprofloxacin (30 mg/kg), cefazolin (100 mg/kg), or ciprofloxacin (30 mg/kg) plus rifampin (20 mg/kg) every 8 h for 8 days or no antibiotic. Antibiotic levels within the abscess exceeded the MIC for the test organism. At the end of treatment, ciprofloxacin was no more effective than the control, animals receiving cefazolin had a mean log10 fall of 2.41 CFU/ml, and animals receiving ciprofloxacin plus rifampin had a mean log10 reduction of 5.06 CFU/ml (P = less than 0.01). Six days after completion of therapy, all abscesses in animals receiving ciprofloxacin plus rifampin were culture negative. Surviving organisms in animals receiving ciprofloxacin or rifampin did not develop resistance to the treatment antibiotics. In vitro time-kill curves performed with logarithmic- and stationary-phase organisms in broth, serum, and abscess fluid supernatants did not correlate with the in vivo results. Neutrophil killing studies of S. aureus pretreated with antibiotics revealed greater killing of organisms pretreated with ciprofloxacin plus rifampin than of those pretreated with cefazolin or ciprofloxacin alone. In conclusion, ciprofloxacin plus rifampin was effective therapy in this staphylococcal abscess model, compared with the moderate efficacy of cefazolin and no effect observed with ciprofloxacin alone. Enhanced neutrophil killing of S. aureus pretreated with antibiotics may be an important mechanism by which bacteria are killed in suppurative infections.


Subject(s)
Abscess/drug therapy , Neutrophils/drug effects , Staphylococcal Infections/drug therapy , Staphylococcus/drug effects , Abscess/microbiology , Animals , Cefazolin/pharmacology , Cefazolin/therapeutic use , Ciprofloxacin/pharmacology , Ciprofloxacin/therapeutic use , Humans , In Vitro Techniques , Microbial Sensitivity Tests , Neutrophils/immunology , Rabbits , Rifampin/pharmacology , Rifampin/therapeutic use , Staphylococcal Infections/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL